[PR Newswire] - SAN DIEGO, July 31, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has closed a registered direct offering of $15 million of ...
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment